Aktis Oncology, Inc. (AKTS)
| Market Cap | 942.10M |
| Revenue (ttm) | 5.56M |
| Net Income | -60.65M |
| EPS | -76.44 |
| Shares Out | 52.52M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 18,621 |
| Open | 18.03 |
| Previous Close | 17.95 |
| Day's Range | 17.63 - 18.18 |
| 52-Week Range | 16.80 - 29.16 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 30.00 (+67.25%) |
| Earnings Date | Nov 14, 2024 |
About AKTS
Aktis Oncology, Inc. operates as a clinical-stage oncology company that engages in the development of targeted radiopharmaceutical therapies for cancer treatment. The company offers a miniprotein radioconjugate platform to discover and develop radiopharmaceutical therapies that deliver the tumor-killing properties of radioisotopes. It offers Nectin-4, a miniprotein radioconjugate for the treatment of locally advanced or metastatic urothelial cancer. Its products include AKY-1189 to deliver a radioisotope to Nectin-4 expressing tumors for the tr... [Read more]
Analyst Summary
According to one analyst, the rating for AKTS stock is "Buy" and the 12-month stock price target is $30.0.
News
Aktis Oncology Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
BOSTON, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (“Aktis”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large pa...
U.S. IPO Weekly Recap: Aktis Oncology Leads As First Sizable 2026 IPO
U.S. IPO Weekly Recap: Aktis Oncology Leads As First Sizable 2026 IPO
Vida Ventures Congratulates Aktis Oncology on Its Entry into the Public Markets
LOS ANGELES & BOSTON--(BUSINESS WIRE)--Vida Ventures (“Vida”), a next-generation life sciences venture firm, today congratulates Aktis Oncology (Nasdaq: AKTS), a clinical-stage biotechnology company a...
Aktis Oncology prices upsized US IPO at $18 per share
Cancer drug developer Aktis Oncology said on Thursday it priced its upsized U.S. initial public offering at $18 per share, raising about $318 million.
Aktis Oncology Announces Pricing of its Upsized Initial Public Offering
BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (“Aktis”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large pa...
Aktis Oncology Pursues $200 Million IPO On Promising Early Stage Studies
Aktis Oncology, Inc. seeks $200 million in IPO funding to advance radiopharmaceutical candidates for solid tumor cancers. AKTS's lead asset [225Ac]Ac-AKY-1189 is in Phase 1b trials, with preliminary r...
U.S. IPO Weekly Recap: Small Issuers And SPACs Join The Pipeline In Short Holiday Week
Seven IPOs and two SPACs submitted filings this week; no pricings this week. The IPO calendar looks quiet for the week ahead, with one small issuer tentatively slated to debut. Street research is expe...
Aktis Oncology files for US IPO as biotech listings rebound
Aktis Oncology filed for an initial public offering in the United States on Friday, as stock market listings from the biotech industry rebound after a slowdown.
Phase 1 solid tumor biotech Aktis Oncology files for a $100 million IPO
Aktis Oncology, a Phase 1 biotech developing targeted radiopharmaceuticals to treat solid tumors, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
Aktis Oncology IPO Registration Document (S-1)
Aktis Oncology has filed to go public with an IPO on the NASDAQ.